IeDEA West -Africa collaboration

IeDEA 西非合作

• 批准号: 8691657
• 负责人: Francois Dabis
• 金额: $ 166.11万
• 依托单位: ADERA
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-07-01 至 2016-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8691657
• 关键词: Acquired Immunodeficiency Syndrome; Address; Adolescent; Adult; Africa; Anti-Retroviral Agents; Antimalarials; Blood Banks; Burkina Faso; Cancer Etiology; Caring; Case Management; Cervical; Child; Childhood; Clinic; Clinical; Collaborations; Country; Data; Data Quality; Databases; Enrollment; Epidemiology; Exposure to; France; Frequencies; Funding; Ghana; Guinea-Bissau; HIV; HIV-1; HIV-2; Hepatitis B; Hepatitis B Virus; Human Resources; Incidence; Individual; Infection; Information Systems; Malaria; Mali; Malignant Childhood Neoplasm; Malignant Neoplasms; Measures; Mission; Monitor; Morbidity - disease rate; Mothers; Natural History; Nigeria; Outcome; Patients; Pediatrics; Pharmaceutical Preparations; Population; Pregnancy Outcome; Principal Investigator; Procedures; Public Health Schools; Reaction; Research; Research Priority; Resistance; Sample Size; Senegal; Services; Site; System; Time; Togo; Training; Treatment outcome; Universities; antiretroviral therapy; cohort; effectiveness measure; experience; improved; meetings; outcome forecast; pregnant; programs; prospective; response; screening; trend

DESCRIPTION (provided by applicant): The WADA (West Africa Data Base on Antiretroviral Therapy) Collaboration is a unique collaboration among cohorts in West Africa with a mission to conduct hypothesis-driven epidemiological research on the prognosis and outcomes of HIV-1 and HIV-2-infected people, including adults, pregnant mothers, and children in care and generally on treatment, as well as HIV-exposed children. Our five-year research plan will focus on scientific questions requiring a large sample size of patients that the contributing cohorts cannot answer individually and which do not overlap with existing projects. During the five years of the next leDEA round, the overall aims of WADA are:1)to measure the effectiveness of combination antiretroviral treatment (ART) in West Africa in the long term, and to assess factors that influence outcomes; 2) to increase the capacity for delivering ART durably in West Africa by increasing the capacity for monitoring clinical outcomes at the individual and population levels in adults and children; 3) to document the morbidity burden in HIV- infected individuals in care in HIV programs throughout West Africa. To date, the pooled database assembled by the WADA Collaboration in the current leDEA cycle includes 33,815 HIV-infected adults and 3,533 HIV- infected children who initiated ART in 26 clinics. The next round will involve 27 HIV centers (adults: 16, pediatrics: 11) in nine countries (Benin, Burkina Faso, Cote d'lvoire, Ghana, Guinea Bissau, Mali, Nigeria, Senegal, Togo). Among them, two new countries (Guinea Bissau and Togo) and five HIV clinics (three adult clinics and two pediatric clinics) are new collaborating centers. WADA is jointly coordinated by the WADA Coordinating Center at the Bordeaux School of Public Health (ISPED) in Bordeaux University, France (Prof. Francois Dabis) with a WADA Regional Office hosted by PAC-CI, a research-oriented non-governmental organization situated in Abidjan, Cote d'lvoire. This research team has a long-lasting experience in observational HIV research including large-scale prospective cohorts in West Africa and will continue and expand the ongoing leDEA-funded cycle. Data will be collected from affiliated cohorts every year according to standardized procedures. Capacity building in participating centers will include funding for local human resources, training on data quality, on-site technical support and annual meetings to reinforce the technical and scientific network. The priority research agenda will address the following topics: retention in care, natural history of HIV-2 and HIV-1/HIV-2 infections, cancer, malaria, hepatitis B, pregnancy outcomes, pharmacovigilance, adolescent and pediatric access and efficiency of care. RELEVANCE: Clinical and operational research assessing the efficiency of HIV care programs require reliable information systems and capacity building for sustaining this activity in the long term. The WADA collaboration has already implemented a network of HIV care centers and will reinforce its commitment to study morbidities including cancer, malaria, hepatitis B and adverse drug reactions. The HIV-2 cohort will be strengthened with the organization of a blood bank Children will be enrolled from the time of HIV exposure.

描述（由申请人提供）： WADA（西非抗逆转录病毒治疗数据库）协作是西非人群之间的一项独特协作，其使命是对HIV-1和HIV-2感染者的预后和结果进行假设驱动的流行病学研究，包括成人、孕妇和接受护理和一般治疗的儿童，以及艾滋病毒暴露儿童。我们的五年研究计划将侧重于需要大量患者样本的科学问题，这些问题是贡献队列无法单独回答的，并且与现有项目不重叠。在下一轮leDEA的五年期间，世界反兴奋剂机构的总体目标是：1）衡量西非抗逆转录病毒综合治疗（ART）的长期有效性，并评估影响结果的因素; 2）通过提高监测成人和儿童个人和人群临床结果的能力，提高西非持久提供ART的能力; 3）记录整个西非艾滋病毒方案中接受护理的艾滋病毒感染者的发病率负担。到目前为止，世界反兴奋剂机构协作组在当前leDEA周期中收集的汇总数据库包括在26个诊所开始抗逆转录病毒治疗的33，815名艾滋病毒感染成人和3，533名艾滋病毒感染儿童。下一轮将涉及9个国家（贝宁、布基纳法索、科特迪瓦、加纳、几内亚比绍、马里、尼日利亚、塞内加尔、多哥）的27个艾滋病毒中心（成人：16个，儿科：11个）。其中，两个新的国家（几内亚比绍和多哥）和五个艾滋病毒诊所（三个成人诊所和两个儿科诊所）是新的合作中心。世界反兴奋剂机构由设在法国波尔多大学波尔多公共卫生学院（ISPED）的世界反兴奋剂机构协调中心（Francois Dabis教授）与设在科特迪瓦阿比让的研究型非政府组织PAC-CI主办的世界反兴奋剂机构区域办事处共同协调。该研究小组在观察性艾滋病毒研究方面拥有长期经验，包括在西非进行大规模前瞻性队列研究，并将继续和扩大正在进行的leDEA资助的周期。每年将根据标准化程序从附属队列中收集数据。参与中心的能力建设将包括为当地人力资源提供资金、数据质量培训、现场技术支持和年度会议，以加强技术和科学网络。优先研究议程将涉及以下主题：继续护理、HIV-2和HIV-1/HIV-2感染的自然史、癌症、疟疾、B型肝炎、妊娠结局、药物警戒、青少年和儿科获得护理的机会和效率。 相关性： 评估艾滋病毒护理方案效率的临床和业务研究需要可靠的信息系统和能力建设，以长期维持这一活动。世界反兴奋剂机构的合作已经建立了一个艾滋病毒护理中心网络，并将加强其对研究癌症、疟疾、B型肝炎和药物不良反应等疾病的承诺。将通过组织一个血库加强艾滋病毒-2队列，儿童将从接触艾滋病毒之时开始登记。